# Huons pharmaceutical and biotechnology developments

> Live situation record from CLSTR: https://clstr.news/situations/huons-pharmaceutical-and-biotechnology-developments
> Updated: 2026-09-14T01:36:37.000Z. Sources: 4. Developments: 2.

Huons Lab, a subsidiary of Huons Global, has secured intellectual property rights for its HyDIFFUZE platform technology. The company completed domestic patent registrations and international patent applications for 11 different antibody drug subcutaneous compositions. This technology uses recombinant human hyaluronidase to improve drug dispersion and absorption in subcutaneous tissue.

Following these developments, Huons was selected for three national drug development projects under a South Korean government initiative. Through these projects, Huons will collaborate with various bio-ventures to accelerate clinical entry for several candidates, including an mRNA-lipid nanoparticle eye drop, an antibody-drug conjugate, and a subcutaneous peptide anticancer agent.

## Timeline

### 2026-09-14: Huons selected for three national drug development projects

Huons has secured three national government projects to co-develop new drug pipelines with bio-ventures Surginex, Pinobio, and Pulse In Myer, focusing on mRNA eye drops, ADCs, and peptide anticancer agents.

3 sources. https://clstr.news/cluster/huons-selected-for-three-national-drug-development-projects

### 2026-08-31: Huons Lab secures patents for HyDIFFUZE antibody subcutaneous compositions

Huons Lab has registered domestic patents and filed PCT applications for 11 antibody drug subcutaneous compositions using its HyDIFFUZE platform, which improves drug exposure and concentration.

3 sources. https://clstr.news/cluster/huons-lab-secures-patents-for-hydiffuze-antibody-subcutaneous-compositions

---
Cite as: Huons pharmaceutical and biotechnology developments. CLSTR, https://clstr.news/situations/huons-pharmaceutical-and-biotechnology-developments